Skip to Content

No altered risk of IBD associated with the overall use of GLP-1 based therapies

In the following MEDtalk, Heidi Søgaard Christensen from PREDICT, Copenhagen, discusses the initial study exploring the impact of GLP-1 based therapies on the likelihood of individuals with type 2-diabetes developing IBD. The investigation was prompted by a prior study that linked the use of DPP4i to a higher risk of inflammatory bowel disease (IBD), although two other studies found no significant changes in risk.

Heidi Søgaard Christensen

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top